MBX Earnings Date: Nov 5, 2026 (Estimated) — MBX Biosciences, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
Updated
When is MBX's next earnings date?
MBX Biosciences, Inc. Common Stock (MBX) is expected to report earnings on Thursday, November 5, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.83.
How did MBX do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q3 2026), MBX Biosciences, Inc. Common Stock posted EPS of -$0.01 versus the -$0.68 estimate, a beat of 99.1%. Revenue was $4.1M against a $3.8M estimate. The stock's 1-day post-earnings move was +0.2%.
How much does MBX stock move after earnings?
MBX beat EPS estimates in 5 of its last 6 reported quarters. Over the last 7 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q3 2026 | -0.68 | -0.01 | +99.12% | $4.1M | ✅ Beat | +0.16% | +2.14% | -11.87% |
| 2026-08-06 | Q2 2026 | -0.63 | -0.78 | -25.81% | $0 | ❌ Miss | -0.55% | -0.76% | -8.98% |
| 2026-05-07 | Q1 2026 | -0.59 | -0.51 | +13.56% | $0 | ✅ Beat | +8.06% | +16.75% | -5.73% |
| 2026-03-12 | Q4 2025 | -0.61 | -0.49 | +19.67% | $0 | ✅ Beat | -3.42% | -0.83% | +7.12% |
| 2025-11-06 | Q3 2025 | -0.69 | -0.63 | +8.70% | $0 | ✅ Beat | +9.71% | +9.09% | +41.77% |
| 2025-03-17 | Q4 2024 | -0.58 | -0.47 | +18.97% | $0 | ✅ Beat | +1.72% | -9.31% | -14.60% |
| 2024-11-07 | Q3 2024 | — | -2.78 | — | $0 | — | +2.07% | -8.35% | -2.51% |
Showing last 7 quarters.